Comorbidity phenotypes and risk of mortality in patients with ischaemic heart disease in the UK.


Journal

Heart (British Cardiac Society)
ISSN: 1468-201X
Titre abrégé: Heart
Pays: England
ID NLM: 9602087

Informations de publication

Date de publication:
06 2020
Historique:
received: 09 10 2019
revised: 27 01 2020
accepted: 28 01 2020
pubmed: 11 4 2020
medline: 16 2 2021
entrez: 11 4 2020
Statut: ppublish

Résumé

The objective of this study is to use latent class analysis of up to 20 comorbidities in patients with a diagnosis of ischaemic heart disease (IHD) to identify clusters of comorbidities and to examine the associations between these clusters and mortality. Longitudinal analysis of electronic health records in the health improvement network (THIN), a UK primary care database including 92 186 men and women aged ≥18 years with IHD and a median of 2 (IQR 1-3) comorbidities. Latent class analysis revealed five clusters with half categorised as a low-burden comorbidity group. After a median follow-up of 3.2 (IQR 1.4-5.8) years, 17 645 patients died. Compared with the low-burden comorbidity group, two groups of patients with a high-burden of comorbidities had the highest adjusted HR for mortality: those with vascular and musculoskeletal conditions, HR 2.38 (95% CI 2.28 to 2.49) and those with respiratory and musculoskeletal conditions, HR 2.62 (95% CI 2.45 to 2.79). Hazards of mortality in two other groups of patients characterised by cardiometabolic and mental health comorbidities were also higher than the low-burden comorbidity group; HR 1.46 (95% CI 1.39 to 1.52) and 1.55 (95% CI 1.46 to 1.64), respectively. This analysis has identified five distinct comorbidity clusters in patients with IHD that were differentially associated with risk of mortality. These analyses should be replicated in other large datasets, and this may help shape the development of future interventions or health services that take into account the impact of these comorbidity clusters.

Identifiants

pubmed: 32273305
pii: heartjnl-2019-316091
doi: 10.1136/heartjnl-2019-316091
pmc: PMC7282548
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

810-816

Subventions

Organisme : Medical Research Council
ID : MR/S027602/1
Pays : United Kingdom
Organisme : British Heart Foundation
Pays : United Kingdom

Commentaires et corrections

Type : CommentIn

Informations de copyright

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

BMJ. 2015 Jan 20;350:h176
pubmed: 25646760
Age Ageing. 2018 Mar 1;47(2):193-200
pubmed: 29040347
Eur J Clin Invest. 2015 Apr;45(4):405-14
pubmed: 25630589
Pharmacoepidemiol Drug Saf. 2013 Jan;22(1):64-9
pubmed: 23124958
Eur Heart J Qual Care Clin Outcomes. 2017 Jan 1;3(1):20-36
pubmed: 28927187
PLoS Med. 2018 Mar 6;15(3):e1002513
pubmed: 29509757
Lancet. 2017 Apr 1;389(10076):1323-1335
pubmed: 28236464
J Gerontol A Biol Sci Med Sci. 2019 Feb 15;74(3):366-372
pubmed: 29562321
BMJ Open. 2016 Sep 20;6(9):e013089
pubmed: 27650770
Transl Res. 2013 Oct;162(4):237-51
pubmed: 23727296
J Comorb. 2018 Oct 14;8(1):2235042X18804063
pubmed: 30364387
JAMA. 2015 Jul 7;314(1):52-60
pubmed: 26151266
BMC Public Health. 2011 Feb 03;11:77
pubmed: 21291555
PLoS One. 2014 Jun 18;9(6):e99825
pubmed: 24941260
BMJ Open Respir Res. 2018 Jun 13;5(1):e000302
pubmed: 29955364
Inform Prim Care. 2011;19(4):251-5
pubmed: 22828580
Pharmacoepidemiol Drug Saf. 2009 Jan;18(1):76-83
pubmed: 19065600
J Stat Softw. 2015 Mar 20;64(7):1-30
pubmed: 27307779
PLoS Comput Biol. 2009 Apr;5(4):e1000353
pubmed: 19360091
J Am Geriatr Soc. 2017 Nov;65(11):2473-2479
pubmed: 28873220
Health Libr Rev. 1994 Sep;11(3):177-82
pubmed: 10139676
Int J Epidemiol. 2018 Oct 1;47(5):1687-1704
pubmed: 30016472
Lancet Respir Med. 2015 Aug;3(8):631-9
pubmed: 26208998
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
PLoS Med. 2018 Mar 6;15(3):e1002501
pubmed: 29509764
Eur J Epidemiol. 2019 Nov;34(11):1025-1053
pubmed: 31624969
Nat Commun. 2014 Jun 24;5:4022
pubmed: 24959948
BMC Geriatr. 2019 Jun 14;19(1):166
pubmed: 31200651
Tuberk Toraks. 2016 Dec;64(4):289-298
pubmed: 28393718

Auteurs

Francesca Crowe (F)

Institute of Applied Health Research, University of Birmingham, Birmingham, UK F.Crowe@bham.ac.uk.

Dawit T Zemedikun (DT)

Institute of Applied Health Research, University of Birmingham, Birmingham, UK.

Kelvin Okoth (K)

Institute of Applied Health Research, University of Birmingham, Birmingham, UK.

Nicola Jaime Adderley (NJ)

Institute of Applied Health Research, University of Birmingham, Birmingham, UK.

Gavin Rudge (G)

Institute of Applied Health Research, University of Birmingham, Birmingham, UK.

Mark Sheldon (M)

Institute of Applied Health Research, University of Birmingham, Birmingham, UK.

Krishnarajah Nirantharakumar (K)

Institute of Applied Health Research, University of Birmingham, Birmingham, UK.

Tom Marshall (T)

Institute of Applied Health Research, University of Birmingham, Birmingham, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH